scholarly journals Amiodarone-Induced Acute Liver Injury

2020 ◽  
Vol 14 (1) ◽  
pp. 87-90
Author(s):  
Rajesh Essrani ◽  
Shehriyar Mehershahi ◽  
Rajesh Kumar Essrani ◽  
Shri Jai Kirshan Ravi ◽  
Sajeer Bhura ◽  
...  
Keyword(s):  
Liver Injury ◽  
Acute Hepatitis ◽  
Injection Site ◽  
Half Life ◽  
Thyroid Dysfunction ◽  
Liver Enzymes ◽  
Acute Liver Injury ◽  
Hepatic Toxicity ◽  
Intravenous Amiodarone

Amiodarone is a lipophilic structure with a half-life of 25–100 days. Long-term oral amiodarone is associated with photosensitivity, thyroid dysfunction, and pulmonary and hepatic toxicity. Intravenous amiodarone can lead to sweating, heating sensation, nausea, phlebitis at the injection site, and rarely acute hepatitis. This is a compelling case of a 60-year-old male who developed acute liver injury 24–36 h after starting amiodarone. All the possible causes of acute liver injury were ruled out, and his liver enzymes improved after discontinuing amiodarone.

Acute Liver Injury Caused by Intravenous Amiodarone;Myoclonus Associated with Long-term Use of Diltiazem;Involuntary Movements Associated with Cetirizine;Cocaine-Induced Ischemic Bowel;Asenapine and Severe Allergic Reactions;Dapsone-Induced Methemoglobinemia;Neurotoxic Effects Associated with Antibiotic Use

2011 ◽  
Vol 46 (11) ◽  
pp. 835-838
Author(s):  
Sinister Joel
Keyword(s):  
Liver Injury ◽  
Acute Liver Injury ◽  
Antibiotic Use ◽  
Allergic Reactions ◽  
Drug Reactions ◽  
Ischemic Bowel ◽  
The Us ◽  
Neurotoxic Effects ◽  
Intravenous Amiodarone

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA's) MEDWATCH program (800-FDA-1088). If you have reported an interesting, preventable ADR to MEDWATCH, please consider sharing the account with our readers.

scholarly journals Disulfiram-Induced Acute Liver Injury

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Lucas Ramer ◽  
Matthieu Tihy ◽  
Nicolas Goossens ◽  
Jean-Louis Frossard ◽  
Laura Rubbia-Brandt ◽  
...  
Keyword(s):  
Liver Injury ◽  
Acute Hepatitis ◽  
Fulminant Hepatitis ◽  
Liver Enzymes ◽  
Drug Withdrawal ◽  
Acute Liver Injury ◽  
True Incidence ◽  
Elevated Liver Enzymes ◽  
Severity Of Injury ◽  
Hepatocyte Necrosis

Disulfiram is a drug used to treat alcohol dependence since many years. It interferes with the metabolism of alcohol, may be associated with neurological and dermatological symptoms, and can be hepatotoxic. Due to the frequent coexistent liver test alterations due to alcohol, the true incidence of disulfiram-associated liver injury is unclear and severity of injury may vary from mildly elevated liver enzymes to fulminant hepatitis leading to death. There are several reported cases of disulfiram hepatitis in the literature. Liver histology, when available, demonstrates some degree of portal inflammation with eosinophils and hepatocyte necrosis. We present here a well-documented case of acute hepatitis due to disulfiram with typical histological lesions, favorable outcome following drug withdrawal, and a brief steroid course. The risk of hepatotoxicity should be kept in mind when prescribing disulfiram.

scholarly journals Short- or long-term high-fat diet feeding plus acute ethanol binge synergistically induce acute liver injury in mice: An important role for CXCL1

Hepatology ◽  
2015 ◽  
Vol 62 (4) ◽  
pp. 1070-1085 ◽  
Author(s):  
Binxia Chang ◽  
Ming-Jiang Xu ◽  
Zhou Zhou ◽  
Yan Cai ◽  
Man Li ◽  
...  
Keyword(s):  
Liver Injury ◽  
High Fat Diet ◽  
Acute Liver Injury ◽  
High Fat ◽  
Acute Ethanol

Acute liver injury after intravenous amiodarone

2011 ◽  
Vol 29 (7) ◽  
pp. 843.e5-843.e6 ◽  
Author(s):  
Andrea Verhovez ◽  
Fabrizio Elia ◽  
Alessandra Riva ◽  
Giovanni Ferrari ◽  
Franco Aprà
Keyword(s):  
Liver Injury ◽  
Acute Liver Injury ◽  
Intravenous Amiodarone

scholarly journals Clozapine-induced liver injury and pleural effusion

2014 ◽  
Vol 6 (2) ◽  
pp. 36-37
Author(s):  
Joseph P.M. Kane ◽  
Francis A. O'Neill
Keyword(s):  
Pleural Effusion ◽  
Liver Injury ◽  
Liver Enzymes ◽  
Clinical Symptoms ◽  
Acute Liver Injury ◽  
Case Reports ◽  
High Index ◽  
Documented Case ◽  
High Index Of Suspicion ◽  
Symptoms And Signs

Clozapine, whilst associated commonly with a transient and benign increase in liver enzymes, has also been associated with varying presentations of hepatitis in existing case reports. This report describes what we believe to be the first documented case of acute liver injury and pleural effusion associated with clozapine, resolving after cessation of the agent. The case supports existing literature in advocating a high index of suspicion, particularly in the 4-5 weeks following clozapine initiation, when considering nonspecific clinical symptoms and signs.

scholarly journals The Hepatoprotection by Oleanolic Acid Preconditioning: Focusing on PPARαActivation

PPAR Research ◽  
2018 ◽  
Vol 2018 ◽  
pp. 1-14 ◽  
Author(s):  
Wenwen Wang ◽  
Kan Chen ◽  
Yujing Xia ◽  
Wenhui Mo ◽  
Fan Wang ◽  
...  
Keyword(s):  
Liver Injury ◽  
Oleanolic Acid ◽  
Molecular Mechanisms ◽  
Liver Enzymes ◽  
Acute Liver Injury ◽  
Inflammatory Factors ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Anti Inflammatory ◽  
Major Factors

Objective. Previous studies have characterized the hepatoprotective and anti-inflammatory properties of oleanolic acid (OA). This study aimed to investigate the molecular mechanisms of OA hepatoprotection in concanavalin A- (ConA-) induced acute liver injury.Materials and Methods. ConA (20 mg/kg) was intravenously injected to induce acute liver injury in Balb/C mice. OA pretreatment (20, 40, and 80 mg/kg) was administered subcutaneously once daily for 3 consecutive days prior to treatment with ConA; 2, 8, and 24 h after ConA injection, the levels of serum liver enzymes and the histopathology of major factors and inflammatory cytokines were determined.Results. OA reduced the release of serum liver enzymes and inflammatory factors and prevented ConA mediated damage to the liver. OA elevated the expression levels of peroxisome proliferator-activated receptor alpha (PPARα) and decreased the phosphorylation of c-Jun NH2-terminal kinase (JNK).Conclusion. OA exhibits anti-inflammatory properties during ConA-induced acute liver injury by attenuating apoptosis and autophagy through activation of PPARαand downregulation of JNK signaling.

scholarly journals Constitutive release of CPS1 in bile and its role as a protective cytokine during acute liver injury

2019 ◽  
Vol 116 (18) ◽  
pp. 9125-9134 ◽  
Author(s):  
Min-Jung Park ◽  
Louis G. D’Alecy ◽  
Michelle A. Anderson ◽  
Venkatesha Basrur ◽  
Yongjia Feng ◽  
...  
Keyword(s):  
Liver Injury ◽  
Liver Damage ◽  
Half Life ◽  
Fas Ligand ◽  
Urea Cycle ◽  
Acute Liver Injury ◽  
Carbamoyl Phosphate ◽  
Human Bile ◽  
Cycle Enzyme ◽  
Short Half Life

Carbamoyl phosphate synthetase-1 (CPS1) is the major mitochondrial urea cycle enzyme in hepatocytes. It is released into mouse and human blood during acute liver injury, where is has a short half-life. The function of CPS1 in blood and the reason for its short half-life in serum are unknown. We show that CPS1 is released normally into mouse and human bile, and pathologically into blood during acute liver injury. Other cytoplasmic and mitochondrial urea cycle enzymes are also found in normal mouse bile. Serum, bile, and purified CPS1 manifest sedimentation properties that overlap with extracellular vesicles, due to the propensity of CPS1 to aggregate despite being released primarily as a soluble protein. During liver injury, CPS1 in blood is rapidly sequestered by monocytes, leading to monocyte M2-polarization and homing to the liver independent of its enzyme activity. Recombinant CPS1 (rCPS1), but not control r-transferrin, increases hepatic macrophage numbers and phagocytic activity. Notably, rCPS1 does not activate hepatic macrophages directly; rather, it activates bone marrow and circulating monocytes that then home to the liver. rCPS1 administration prevents mouse liver damage induced by Fas ligand or acetaminophen, but this protection is absent in macrophage-deficient mice. Moreover, rCPS1 protects from acetaminophen-induced liver injury even when given therapeutically after injury induction. In summary, CPS1 is normally found in bile but is released by hepatocytes into blood upon liver damage. We demonstrate a nonenzymatic function of CPS1 as an antiinflammatory protective cytokine during acute liver injury.

scholarly journals Acute Hepatitis E is an Underreported Cause of Severe Acute Liver Injury

2019 ◽  
Vol 17 (5) ◽  
pp. 1004-1006 ◽  
Author(s):  
Stefanie Quickert ◽  
Philipp A. Reuken ◽  
Michael Rose ◽  
Katharina Boden ◽  
Tony Bruns
Keyword(s):  
Liver Injury ◽  
Acute Hepatitis ◽  
Acute Liver Injury ◽  
Hepatitis E ◽  
Acute Hepatitis E

scholarly journals Acute icteric hepatitis as the first isolated symptom of COVID-19

2021 ◽  
Vol 14 (6) ◽  
pp. e242853
Author(s):  
Pierre-Clément Thiebaud ◽  
Christelle Hermand ◽  
Jennifer Sobotka ◽  
Pierre-Alexis Raynal
Keyword(s):  
Liver Injury ◽  
Acute Hepatitis ◽  
Clinical Presentation ◽  
Liver Enzymes ◽  
Healthy Patient ◽  
Moderate Elevation

Patients with COVID-19 may be asymptomatic or present with extrarespiratory symptoms, such as liver injury. It has been reported that 22.5%–46.2% of patients have moderate elevation of liver enzymes. To our knowledge, acute hepatitis has never been described as an isolated symptom of COVID-19 in a previously healthy patient. We report the case of a 53-year-old patient with COVID-19 whose first clinical presentation was acute icteric hepatitis, several days before the development of others symptoms. During the pandemic, we suggest that patients with acute hepatitis be considered as COVID-19 suspects, tested and isolated.

scholarly journals Rare Incidence of Acute Liver Injury with Potassium Para-Aminobenzoate Introduction

2018 ◽  
Vol 12 (2) ◽  
pp. 230-233 ◽  
Author(s):  
Layth Al Attar ◽  
Wiliam Kilgore
Keyword(s):  
Liver Injury ◽  
Side Effect ◽  
Liver Enzymes ◽  
Acute Liver Injury ◽  
Peyronie’S Disease ◽  
Quadrant Pain ◽  
Elevated Liver Enzymes ◽  
Peyronie's Disease ◽  
New Treatment ◽  
The Many

Acute liver injury is an alarming condition, as it may lead to a devastating outcome. Of the many causes of acute liver injury, review of medications is crucial to identifying the cause of the injury. Some commonly used medications may unpredictably be the underlying cause of liver injury. We present a case of Peyronie’s disease treated with potassium para-aminobenzoate that developed acute liver injury. After starting the new treatment, the patient complained of right upper quadrant pain. He was found to have elevated liver enzymes. The condition resolved after stopping potassium para-aminobenzoate use. We report a potassium para-aminobenzoate side effect of liver injury that can be managed conservatively.

Sign in / Sign up

Export Citation Format

Share Document